Janus Henderson Group PLC Sells 164,552 Shares of Zoetis Inc. (NYSE:ZTS)

Janus Henderson Group PLC reduced its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 9.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,606,508 shares of the company's stock after selling 164,552 shares during the quarter. Janus Henderson Group PLC owned 0.36% of Zoetis worth $261,756,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Callahan Advisors LLC boosted its holdings in Zoetis by 90.4% during the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock valued at $2,135,000 after acquiring an additional 6,221 shares during the period. CIBC Asset Management Inc raised its position in Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after purchasing an additional 46,050 shares in the last quarter. Schroder Investment Management Group raised its position in Zoetis by 2.6% in the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock worth $40,036,000 after purchasing an additional 6,169 shares in the last quarter. PFW Advisors LLC bought a new position in Zoetis in the 4th quarter valued at $1,764,000. Finally, Vanguard Group Inc. grew its holdings in Zoetis by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock worth $6,739,905,000 after acquiring an additional 120,158 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Piper Sandler lifted their target price on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday. Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. UBS Group reduced their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Finally, Stifel Nicolaus reduced their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $212.75.

Zoetis Stock Up 3.4%

Shares of ZTS traded up $5.34 during midday trading on Thursday, hitting $160.26. The stock had a trading volume of 3,536,194 shares, compared to its average volume of 2,511,454. The company has a 50 day simple moving average of $156.72 and a two-hundred day simple moving average of $165.71. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The firm has a market cap of $71.35 billion, a price-to-earnings ratio of 29.30, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter last year, the business posted $1.38 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares of the company's stock, valued at $2,682,770. The trade was a 2.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.